- Home
- CBIO vs GPRK Comparison
CBIO vs GPRK Comparison
Compare CBIO & GPRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- GPRK
- Stock Information
- Founded
- CBIO 2003
- GPRK 2002
- Country
- CBIO United States
- GPRK Colombia
- Employees
- CBIO N/A
- GPRK N/A
- Industry
- CBIO
- GPRK Oil & Gas Production
- Sector
- CBIO
- GPRK Energy
- Exchange
- CBIO Nasdaq
- GPRK Nasdaq
- Market Cap
- CBIO 308.0M
- GPRK 338.2M
- IPO Year
- CBIO N/A
- GPRK N/A
- Fundamental
- Price
- CBIO $12.85
- GPRK $6.47
- Analyst Decision
- CBIO Strong Buy
- GPRK Buy
- Analyst Count
- CBIO 3
- GPRK 1
- Target Price
- CBIO $25.67
- GPRK $11.00
- AVG Volume (30 Days)
- CBIO 108.6K
- GPRK 495.3K
- Earning Date
- CBIO 07-31-2025
- GPRK 08-05-2025
- Dividend Yield
- CBIO N/A
- GPRK 8.96%
- EPS Growth
- CBIO N/A
- GPRK N/A
- EPS
- CBIO N/A
- GPRK 0.81
- Revenue
- CBIO N/A
- GPRK $560,354,000.00
- Revenue This Year
- CBIO N/A
- GPRK N/A
- Revenue Next Year
- CBIO N/A
- GPRK $3.01
- P/E Ratio
- CBIO N/A
- GPRK $8.14
- Revenue Growth
- CBIO N/A
- GPRK N/A
- 52 Week Low
- CBIO $10.90
- GPRK $5.66
- 52 Week High
- CBIO $21.40
- GPRK $11.72
- Technical
- Relative Strength Index (RSI)
- CBIO N/A
- GPRK 42.12
- Support Level
- CBIO N/A
- GPRK $6.38
- Resistance Level
- CBIO N/A
- GPRK $6.88
- Average True Range (ATR)
- CBIO 0.00
- GPRK 0.25
- MACD
- CBIO 0.00
- GPRK -0.02
- Stochastic Oscillator
- CBIO 0.00
- GPRK 27.96
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.